A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato) oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats

Experimental Biology and Medicine

Volumn 230, Issue 3, 2005, Pages 207-216

  Winter, Carol L ^a   Lange, Jana S ^a   Davis, Michael G ^a   Gerwe, Gina S ^a   Downs, Thomas R ^a   Peters, Kevin G ^a   Kasibhatla, Bhavani ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Adiponectin; BMOV; Insulin sensitivity; Protein tyrosine phosphatase; ZDF rat

Indexed keywords

ADIPONECTIN; BIS(MALTOLATO)OXOVANADIUM; GLUCOSE; PROTEIN TYROSINE PHOSPHATASE; ROSIGLITAZONE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; FLUID INTAKE; FOOD INTAKE; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPERINSULINISM; HYPERPHAGIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; PANCREAS ISLET; POLYDIPSIA; RAT; RAT STRAIN; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 14344255690     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000307     Document Type: Article

References (53)

1. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992.
2. Vague P, Raccah D. The syndrome of insulin resistance. Horm Res 38:28-32, 1992.
3. Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 43:735-740, 1994.
4. Reaven GM. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev 9(Suppl 1):5S-12S, 1993.
5. White MF, Kahn CR. The insulin signaling system. J Biol Chem 269:1-4, 1994.
6. Saltiel AR. Diverse signaling pathways in the cellular actions of insulin. Am J Physiol 270:E375-E385, 1996.
7. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084, 1994.
8. Seely BL, Staubs PA, Reichart DR, Berhanu P, Milarski KL, Saltiel AR, Kusari J, Olefsky JM. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45:1379-1385, 1996.
9. Wang XY, Bergdahl K, Heijbel A, Liljebris C, Bleasdale JE. Analysis of in vitro interactions of protein tyrosine phosphatase 1B with insulin receptors. Mol Cell Endocrinol 173:109-120, 2001.
10. Bandyopadhyay D, Kusari A, Kenner KA, Liu F, Chernoff J, Gustafson TA, Kusari J. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 272:1639-1645, 1997.
11. Ramachandran C, Aebersold R, Tonks NK, Pot DA. Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases. Biochemistry 31:4232-4238, 1992.
12. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ. Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. J Biol Chem 270:20503-20508, 1995.
13. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544-1548, 1999.
14. Ahmad F, Azevedo JL, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 100:449-458, 1997.
15. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism 46:1140-1145, 1997.
16. Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, Soccio T, Mastroianno S, Tassi V, Almgren P, Pizzuti A, Vigneri R, Trischitta V. A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 70:806-812, 2002.
17. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, Xie N, Wilcox D, Jacobson P, Frost L, Kroeger PE, Reilly RM, Koterski S, Opgenorth TJ, Ulrich RG, Crosby S, Butler M, Murray SF, McKay RA, Bhanot S, Monia BP, Jirousek MR. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 99:11357-11362, 2002.
18. Blaskovich M, Kim HO. Recent discovery and development of protein tyrosine phophatase inhibitors. Expert Opin Ther Patents 12:871-905, 2002.
19. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18-19, 1996.
20. Peterson RG. The Zucker diabetic fatty (ZDF) rat. In: Shafrir E, Ed. Lessons From Animal Diabetes. London: Smith-Gordon, p225, 1995.
21. Janssen SW, Hermus AR, Lange WP, Knijnenburg Q, van der Laak JA, Sweep CG, Martens GJ, Verhofstad AA. Progressive histopathological changes in pancreatic islets of Zucker diabetic fatty rats. Exp Clin Endocrinol Diabetes 109:273-282, 2001.
22. Buckingham RE, Al Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334, 1998.
23. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2:363-372, 2000.
24. Badmaev V, Prakash S, Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J Altern Complement Med 5:273-291, 1999.
25. Balasubramanyam M, Mohan V. Orally active insulin mimics: where do we stand now? J Biosci 26:383-390, 2001.
26. Salice VC, Cortizo AM, Gomez Dumm CL, Etcheverry SB. Tyrosine phosphorylation and morphological transformation induced by four vanadium compounds on MC3T3E1 cells. Mol Cell Biochem 198:119-128, 1999.
27. Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 74:1001-1009, 1996.
28. Yuen VG, Bhanot S, Battell ML, Orvig C, McNeill JH. Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats. Can J Physiol Pharmacol 81:1049-1055, 2003.
29. Mohammad A, Wang J, McNeill JH. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTPlB in Zucker rat skeletal muscle in vivo. Mol Cell Biochem 229:125-128, 2002.
30. Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorganic Biochem 96:321-330, 2003.
31. Yuen VG, Vera E, Battell ML, Li WM, McNeill JH. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Diabetes Res Clin Pract 43:9-19, 1999.
32. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 47:177-184, 2000.
33. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired multimerization of human adiponectin mutants associated with diabetes - molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003.
34. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979.
35. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058, 2001.
36. Eigen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49:684-688, 2000.
37. Griffen SC, Wang J, German MS. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 50:63-68, 2001.
38. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996.
39. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 271:E742-E747, 1996.
40. Peterson RG. alpha-Glucosidase inhibitors in diabetes: lessons from animal studies. Eur J Clin Invest 24(Suppl 3):11-18, 1994.
41. Wang J, Yuen VG, McNeill JH. Effect of vanadium on insulin sensitivity and appetite. Metabolism 50:667-673, 2001.
42. Wang J, Yuen VG, McNeill JH. Effect of vanadium on insulin and leptin in Zucker diabetic fatty rats. Mol Cell Biochem 218:93-96, 2001.
43. Yuen VG, Orvig C, McNeill JH. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats. Am J Physiol 272:E30-E35, 1997.
44. Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol Sci 20:43-46, 1999.
45. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am J Surg 183:430-434, 2002.
46. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128, 2002.
47. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999.
48. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000.
49. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001.
50. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001.
51. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002.
52. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002.
53. Tokuyama Y, Stuns J, DePaoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, Bell GI. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447-1457, 1995.